Our results correspond well with earlier studies that identified the HER2/CEP17 ratio as an important predictive factor, independent of HER2 immunohistochemistry, in advanced HER2-amplified breast cancer [29]. This evidence concerns the gene ERBB2 and breast carcinoma.